Eisai Co Ltd

Read how Eisai’s LITESPARK‑012 failure reshapes its RCC strategy and what Merck & Co. can learn for future oncology collaborations.

Neutral interim results from Eisai’s LITESPARK‑012 trial show adding a HIF‑2α inhibitor to anti‑PD‑1 plus kinase inhibitor doesn’t improve survival in advanced RCC.

How the Cochrane review debunks Alzheimer’s antibody therapies, exposes safety risks, and reshapes market & regulatory expectations for the future of neuro‑degenerative treatments.

Explore how Eisai’s strategic collaborations with Allarity Therapeutics and Newron Pharmaceuticals accelerate oncology drug development, boosting patient outcomes and market reach.

Explore Eisai’s 2025 results and 2026 outlook for lecanemab, highlighting long‑term patient retention, safety, and FDA/EMA regulatory prospects in Alzheimer’s therapy.

Newron Pharmaceuticals reveals Evenamide’s breakthrough glutamate‑modulating data ahead of SIRS 2026, positioning a first‑in‑class therapy for treatment‑resistant schizophrenia, with strategic pricing, patent, and partnership plans that could drive …

Discover how Eisai’s lecanemab presentation at AD/PD 2026 will shape Alzheimer’s treatment—clinical breakthroughs, reimbursement insights, and market strategy revealed.

WELIREG + Lenvima’s 30% PFS boost in RCC promises higher U.S. reimbursement, first‑mover advantage and $600 M annual sales – learn how Eisai will capture this growing market.

Discover how Eisai’s Kompass platform and Leqembi therapy blend digital health, patient care, and oncology‑neuro synergy to reshape pharma.

How Eisai’s Lecanemab review shows the cost‑benefit gap in Alzheimer’s drugs—and why Germany’s value‑based reimbursement forces pharma to prove real clinical value.